Typing of Mycoplasma pneumoniae by multiple-locus variablenumber tandem repeat analysis (MLVA) is increasingly in use.
Introduction
Mycoplasma pneumoniae causes human respiratory tract infections [1] . Typing of isolates and positive clinical samples is necessary to support epidemiologic data for the detection of outbreaks and understand the transmission of infection. In contrast to typing based on sequence differences in the P1 gene of M. pneumoniae [2] , multiple-locus variable-number tandem repeat analysis (MLVA) is reportedly highly discriminatory [3] and is now increasingly in use for strain characterization internationally [4] [5] [6] [7] [8] [9] [10] [11] . Investigating the five loci selected (MPN1, MPN13-16), it has been reported that the MPN1 locus is not stable, thus calling into question the reliability of the marker [12] . Therefore, several authors have proposed an alteration to the naming system to reflect this [12, 13] . Despite the availability of general guidelines for the MLVA procedure [14, 15] , specific internationally agreed guidelines for the execution and interpretation of MLVA of M. pneumoniae are not yet available.
In this study, 24 M. pneumoniae clinical isolates were included, as well as the reference strain M129 (ATCC 29342). The clinical isolates, all derived from sputum specimens, were obtained from the Public Health England Respiratory and Vaccine Preventable Bacteria Reference Unit culture collection. DNA was extracted from bacterial cultures in Mycoplasma liquid medium (Mycoplasma Experience Ltd., UK) using the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche). The commercial quantitative type strain NCTC10119 FH (Minerva Biolabs) was used to determine sensitivity of MLVA at four dilutions (1000, 100, 10 and 1 copy/μL). MLVA was performed in a blinded manner using a previously described method [3] in six international laboratories (China, England, France, Germany, Netherlands, United States of America). Results were collated, including fragment size, calculated MLVA repeat number and MLVA profile. No guidelines were given to the participating laboratories other than that already available in the literature. Naming of profiles was based on the method in which naming is [5] . 'No amplification' was assigned to loci that failed to amplify [16] .
Results
Regarding fragment sizes, excellent parity was seen among laboratories, with <7 bp difference in fragment sizes between all DNA samples and all laboratories. Table 1 includes expected fragment size and repeat numbers in order to clarify predicted fragment size and repeat number. Regarding the fragment repeat numbers, a total of three errors on assigning and collating the MLVA repeat number from the accurate fragment size (transcription errors) were noted from two separate laboratories (Table 2 ). In addition, there was an inconsistency in the results reported for two of the loci, MPN13 and MPN15. This was due to a different interpretation of fragment repeat number when encountering a point number. Specifically, four of the laboratories rounded 3.2 copies up to 4 repeats for MPN13, whereas two other laboratories rounded <3.5 down to 3 repeats. This highlights the need for an internationally agreed protocol regarding the interpretation of MLVA repeat numbers. In addition, one laboratory made calculating errors linked to the determination of the sequence of MPN15. The MPN15 sequence was manually determined as TGTCCATTTTTACTTCCATCAT, in contrast to the accurate TTGTCCATTTTTTCTTCCATC sequence calculated using tandem repeat finder software with settings match, mismatch, indel of (2, 3, 5) . It should be noted that the use of settings other than (2,3,5) can give alternative repeat sequence and length for some loci. For example, using settings (2,7,7) for M. pneumoniae M129, the MPN15 repeat would be only 20 bp with a different sequence (TTGTCCATTTTTTTTCCATC instead of TTGTCCATTTTTTCTTCCATC). Excluding the three transcription errors, and after correcting for interpretation differences by rounding up partial repeat numbers to the next integer value, all laboratories determined identical fragment repeat numbers for the M129 strain, and 20 of the 24 clinical isolates gave consistent fragment repeat numbers (Table 2) . Actual technical differences were seen in only four samples: samples 8, 10, 21 and 30. Interestingly, these samples had lower-than-average DNA concentration on initial DNA extraction (less than 3 μg/mL DNA, compared to 7 μg/ mL for the other samples). To compare the sensitivity, a serial dilution of the NCTC10119 strain was included. All laboratories determined the MLVA profile in the presence of 1000 copies/μL. However, only three laboratories obtained a full profile, while the other three reported partial profiles for the 100 copies/μL standard; two of these partial profiles differed in the repeat number for MPN14. A full profile was obtained with the 10 copies/μL standard by only two laboratories. None of the laboratories obtained a full profile for the lowest dilution tested (1 copy/μL). When examining both the serial dilution and the low-loaded sample results, it was apparent that in laboratory 5, which increased the number of amplification cycles to 45 for samples that gave poor results with 25 cycles of amplification, the typing method showed a greater sensitivity.
Discussion
This study highlights the need for standardization of interpretive criteria for data analysis internationally. It indicates that comparison of existing published MLVA data between laboratories may be flawed in some cases, diminishing reliability of strain investigation involving more than one laboratory. The following recommendations are considered pertinent by our collaborative group in enabling standardization of interpretive data.
First, predicted fragment sizes and repeat numbers should be assigned using the information provided in Table 1 . Sequence of repeat fragments listed in Table 1 should be considered as the sequence of interest.
Second, If tandem repeat finder software is used (http:// tandem.bu.edu/trf/trf.html) [17] to determine repeat numbers, the following settings should be used: match, mismatch, indel (2, 3, 5) .
Third, the repeat number should be expressed as whole integers, and partial sequences should be rounded up to the next integer number. The rounding up or down convention is matter of debate [14, 15] . However, as previously reported [15] , rounding the partial number of repeats up and not down will avoid rounding down to zero a repeat number such as 0.7, which is ambiguous, as it may be understood as 'lack of repeat.' Thus, using a 'rounding up' convention, zero will unambiguously be defined as 'lack of repeat.' Moreover, by retaining a rounding-up approach, future data will correspond with historical data in previous publications related to M. pneumoniae MLVA typing.
Fourth, the MPN1 target should be removed from future analyses due to its instability [12, 13] . The identification of additional MLVA targets that have greater stability than target MPN1 and enable greater discrimination power than MPN16 should be advanced. With the removal of the MPN1 allele, adoption of the following naming system is recommended: MLVA-1, -2, -3 and -4, where each digit corresponds to repeat numbers at loci MPN13, MPN14, MPN15 and MPN16, respectively.
In conclusion, although whole genome sequencing has become rapid and affordable to replace older typing methods in the future for either clinical strains or clinical specimens [18] , MLVA typing using the method by Dégrange et al. [3] is widely in use for M. pneumoniae. MLVA typing was performed with good correlation in six international laboratories, indicating that this methodology can be correctly performed on M. pneumoniae at different locations. Differences due to interpretation of fragment size, repeat sequence identification and repeat numbering led to inconsistencies in the final profiles assigned by laboratories. With users following the interpretation guidelines we provide, full interlaboratory strain comparison should be achieved.
